Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders

Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders. Deal includes reSET , cleared by FDA for treatment of patients with Substance Use Disorder, and reSET-O(TM), potential treatment pending FDA clearance for patients with Opioid Use Disorder treated with buprenorphine  Combines Sandoz expertise in launching / commercializing treatments with Pear's expertise in developing prescription digital therapeutics  Sandoz and Novartis continue to embrace emerging digital technologies to enhance R&D and deliver better outcomes for patients Holzkirchen, April 18, 2018 - Sandoz, a Novartis division, announced today that it has entered into a collaboration with Pear Therapeutics to commercialize and continued development of novel prescription digital therapeutics designed to effectively treat disease and improve clinical outcomes for patients. The collaboration brings together Sandoz expertise in launching and commercializing treatments with Pear's leading experience in digital therapeutics design and implementation. Sandoz and Pear will work together to bring reSET * to patients with Substance Use Disorder and, if cleared by FDA, reSET-O (TM) * to patients with Opioid Use Disorder who are currently receiving buprenorphine, to better address the full burden of their illnesses. Pear's flagship digital therapeutic, reSET, was cleared by the FDA in September 2017 to help treat Substance Use Disorder.